Codexis, Inc. has extended the term of an existing research agreement with Bristol-Myers Squibb and will receive an undisclosed milestone payment for having successfully achieved the program’s research milestone. The research agreement focused on improving biocatalyst productivity for an undisclosed product candidate in the BMS pipeline using Codexis’ proprietary MolecularBreeding directed evolution platform. Under the extended term of the agreement Codexis will receive addition...